Nasdaq

ALK – Financial calendar for the 2018 financial year

20-12-2017

Copenhagen, 2017-12-20 11:06 CET (GLOBE NEWSWIRE) --

2018 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF):

Silent period 9 January 2018
Annual report 2017 6 February 2018
Annual General Meeting to be held 12 March 2018
at ALK 4.00 p.m.
Bøge Allé 1
2970 Hørsholm, Denmark
Written requests to have specific business
transacted at the AGM will be included in the
agenda if received by the company on
26 January 2018 at the latest
(may be e-mailed to investor@alk.net)

Silent period 6 April 2018
Three-month interim report (Q1) 2018 4 May 2018
Silent period 18 July 2018
Six-month interim report (Q2) 2018 15 August 2018
Silent period 12 October 2018
Nine-month interim report (Q3) 2018 9 November 2018

ALK-Abelló A/S

For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Jeppe Ilkjær, tel. +45 7877 4532, mobile +45 3050 2014

About ALK
ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is a world leader in allergy immunotherapy – a treatment of the underlying cause of allergy. The company has approximately 2,300 employees, with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Torii, Abbott, and Seqirus to commercialise sublingual allergy immunotherapy tablets in Japan, Russia, and South-East Asia, and Australia and New Zealand, respectively. The company is headquartered in Hørsholm, Denmark, and listed on Nasdaq Copenhagen. Find more information at www.alk.net.